Cargando…

Nutraceuticals in the Management of Dyslipidemia: Which, When, and for Whom? Could Nutraceuticals Help Low-Risk Individuals with Non-optimal Lipid Levels?

PURPOSE OF REVIEW: The aim of this review is to summarize the available clinical efficacy and safety data related to the most studied and used lipid-lowering nutraceuticals. RECENT FINDINGS: A growing number of meta-analyses of randomized clinical trials supports the effectiveness and tolerability o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cicero, Arrigo F. G., Fogacci, Federica, Stoian, Anca Pantea, Vrablik, Michal, Al Rasadi, Khalid, Banach, Maciej, Toth, Peter P., Rizzo, Manfredi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2021
Materias:	Nonstatin Drugs (M. Vrablik, Section Editors)
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8332568/ https://www.ncbi.nlm.nih.gov/pubmed/34345932 http://dx.doi.org/10.1007/s11883-021-00955-y

Ejemplares similares

The Role of Nutraceuticals in the Optimization of Lipid-Lowering Therapy in High-Risk Patients with Dyslipidaemia
por: Penson, Peter E., et al.
Publicado: (2020)

RNA Silencing in the Management of Dyslipidemias
por: Henney, Neil C., et al.
Publicado: (2021)

Rare Treatments for Rare Dyslipidemias: New Perspectives in the Treatment of Homozygous Familial Hypercholesterolemia (HoFH) and Familial Chylomicronemia Syndrome (FCS)
por: D’Erasmo, Laura, et al.
Publicado: (2021)

Selective Peroxisome Proliferator–Activated Receptor Alpha Modulators (SPPARMα): New Opportunities to Reduce Residual Cardiovascular Risk in Chronic Kidney Disease?
por: Fruchart, Jean-Charles, et al.
Publicado: (2020)

Lomitapide–a Microsomal Triglyceride Transfer Protein Inhibitor for Homozygous Familial Hypercholesterolemia
por: Stefanutti, Claudia
Publicado: (2020)

Monoclonal Antibodies in the Management of Familial Hypercholesterolemia: Focus on PCSK9 and ANGPTL3 Inhibitors
por: Pirillo, Angela, et al.
Publicado: (2021)

Oral Lipid-Lowering Treatments Beyond Statins: Too Old and Outdated or Still Useful?
por: Parhofer, Klaus G.
Publicado: (2021)

Managing of Dyslipidaemia Characterized by Accumulation of Triglyceride-Rich Lipoproteins
por: Visser, Jolien, et al.
Publicado: (2022)

Nutraceuticals and Hypertensive Disorders in Pregnancy: The Available Clinical Evidence
por: Fogacci, Silvia, et al.
Publicado: (2020)

Bempedoic Acid: for Whom and When
por: Ruscica, Massimiliano, et al.
Publicado: (2022)

Nutraceuticals as Modulators of Immune Function: A Review of Potential Therapeutic Effects
por: Medoro, Alessandro, et al.
Publicado: (2023)

Short-Term Effects of a Combined Nutraceutical on Lipid Level, Fatty Liver Biomarkers, Hemodynamic Parameters, and Estimated Cardiovascular Disease Risk: A Double-Blind, Placebo-Controlled Randomized Clinical Trial
por: Cicero, Arrigo F. G., et al.
Publicado: (2017)

Novel Pharmaceutical and Nutraceutical-Based Approaches for Cardiovascular Diseases Prevention Targeting Atherogenic Small Dense LDL
por: Vekic, Jelena, et al.
Publicado: (2022)

Red Yeast Rice for the Improvement of Lipid Profiles in Mild-to-Moderate Hypercholesterolemia: A Narrative Review
por: Cicero, Arrigo F. G., et al.
Publicado: (2023)

The role of nutraceuticals in heart failure muscle wasting as a result of inflammatory activity. The International Lipid Expert Panel (ILEP) Position Paper
por: Bielecka-Dabrowa, Agata, et al.
Publicado: (2023)

The Role of Advanced Glycation End Products on Dyslipidemia
por: Vekic, Jelena, et al.
Publicado: (2023)

Lipid-Lowering Nutraceuticals for an Integrative Approach to Dyslipidemia
por: Cheung, Brian, et al.
Publicado: (2023)

Pemafibrate, a New Selective PPARα Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases
por: Yamashita, Shizuya, et al.
Publicado: (2020)

Lipid lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel
por: Cicero, Arrigo F.G., et al.
Publicado: (2017)

Nutraceutical Approach to Chronic Osteoarthritis: From Molecular Research to Clinical Evidence
por: Colletti, Alessandro, et al.
Publicado: (2021)

Niacin Alternatives for Dyslipidemia: Fool’s Gold or Gold Mine? Part II: Novel Niacin Mimetics
por: Goel, Harsh, et al.
Publicado: (2016)

Niacin Alternatives for Dyslipidemia: Fool’s Gold or Gold Mine? Part I: Alternative Niacin Regimens
por: Dunbar, Richard L., et al.
Publicado: (2016)

Nutraceuticals for the Control of Dyslipidaemias in Clinical Practice
por: Penson, Peter E., et al.
Publicado: (2021)

Effects of a Combined Nutraceutical on Lipid Pattern, Glucose Metabolism and Inflammatory Parameters in Moderately Hypercholesterolemic Subjects: A Double-blind, Cross-over, Randomized Clinical Trial
por: Cicero, Arrigo Francesco Giuseppe, et al.
Publicado: (2016)

Diets, Foods and Food Components’ Effect on Dyslipidemia
por: Fogacci, Federica, et al.
Publicado: (2021)

Comparative effect of a nutraceutical compound based on a flavonoid complex from bergamot on plasma lipids, glucose metabolism, and liver enzymes: a 3-arm, double-blind, placebo-controlled, randomized clinical trial
por: Fogacci, Federica, et al.
Publicado: (2022)

Nutraceutical Approach to Non-Alcoholic Fatty Liver Disease (NAFLD): The Available Clinical Evidence
por: Cicero, Arrigo F. G., et al.
Publicado: (2018)

Effect of combined lipid-lowering and antioxidant nutraceutical on plasma lipids, endothelial function, and estimated cardiovascular disease risk in moderately hypercholesterolemic patients: a double-blind, placebo-controlled randomized clinical trial
por: Cicero, Arrigo F.G., et al.
Publicado: (2021)

Hypertension and Dyslipidemia Combined Therapeutic Approaches
por: Borghi, Claudio, et al.
Publicado: (2022)

Nutraceuticals and Bioactive Components from Fish for Dyslipidemia and Cardiovascular Risk Reduction
por: Chiesa, Giulia, et al.
Publicado: (2016)

Nutraceutical Effects on Glucose and Lipid Metabolism in Patients with Impaired Fasting Glucose: A Pilot, Double-Blind, Placebo-Controlled, Randomized Clinical Trial on a Combined Product
por: Cicero, Arrigo Francesco Giuseppe, et al.
Publicado: (2017)

Nutraceuticals for geriatrics
por: Gupta, Charu, et al.
Publicado: (2014)

Microalgae Nutraceuticals
por: Nicoletti, Marcello
Publicado: (2016)

Novel Therapeutical Approaches to Managing Atherosclerotic Risk
por: Giglio, Rosaria Vincenza, et al.
Publicado: (2021)

Nutrition, Nutraceuticals and Bioactive Compounds in the Prevention and Fight against Inflammation
por: Surma, Stanisław, et al.
Publicado: (2023)

Testing the Short-Term Efficacy of a Lipid-Lowering Nutraceutical in the Setting of Clinical Practice: A Multicenter Study
por: Cicero, Arrigo F.G., et al.
Publicado: (2015)

Atherosclerosis Development and Progression: The Role of Atherogenic Small, Dense LDL
por: Vekic, Jelena, et al.
Publicado: (2022)

Obesity, diet and nutraceuticals
por: Di Lorenzo, Cherubino, et al.
Publicado: (2015)

Nutraceuticals in Parkinson’s Disease
por: Hang, Liting, et al.
Publicado: (2016)

Nutraceuticals: A Review
por: Souyoul, Skylar A., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_qbhal7krh4bff5fdl3lqg64rgd